Lepu Biopharma
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel antibody-based therapies for oncology and immunology.
OncologyImmunology
Technology Platform
Antibody engineering platform for developing bispecific antibodies and antibody-drug conjugates (ADCs) with enhanced targeting capabilities.
Opportunities
Expansion into global markets through partnerships and clinical trials outside China presents significant growth potential.
Risk Factors
Clinical trial failures or regulatory hurdles in key programs could impact valuation and pipeline progression.
Competitive Landscape
Faces strong competition in oncology from both large global pharma and agile Chinese biotechs, particularly in the crowded ADC and bispecific antibody space.